



Congenital aganglionic megacolon (Hirschsprung disease)

Authors: David E Wesson, MD, Monica Esperanza Lopez, MD, MS

Section Editors: Jonathan I Singer, MD, B UK Li, MD

Deputy Editor: Alison G Hoppin, MD

[Contributor Disclosures](#)

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

Literature review current through: Dec 2021. | **This topic last updated:** Oct 07, 2021.

INTRODUCTION

Hirschsprung disease (HD) is a motor disorder of the gut, which is caused by the failure of neural crest cells (precursors of enteric ganglion cells) to migrate completely during intestinal development during fetal life. The resulting aganglionic segment of the colon fails to relax, causing a functional obstruction.

The pathogenesis, diagnosis, and clinical management of HD are discussed below. The emergency complications of HD, including acute obstruction in the neonate, Hirschsprung-associated enterocolitis (HAEC), and volvulus, are discussed in a separate topic review. (See ["Emergency complications of Hirschsprung disease"](#).)

WES RM

EPIDEMIOLOGY

HD occurs in approximately 1 in 5000 live births, with an overall male:female ratio of 3:1 to 4:1; when the entire colon is involved, the sex ratio more nearly approaches 1:1 [1-3]. There is familial clustering for nonsyndromic HD, with an overall recurrence risk of approximately 3 percent in siblings for short-segment disease or up to 17 percent if the proband has long-segment disease [4]. This sibling recurrence risk is higher if the proband is a female and is also higher if multiple family members are affected.

PATHOPHYSIOLOGY

The most accepted theory of the cause of HD is that there is a defect in the craniocaudal migration of neuroblasts originating from the neural crest, a process that begins at four weeks of gestation and ends at week 7 with the arrival of neural crest-derived cells at the distal end of the colon [5]. In Hirschsprung disease, the cells fail to reach the distal colon, rendering that segment aganglionic and therefore with abnormal motor function, resulting in HD. Defects in the differentiation of neuroblasts into ganglion cells and ganglion cell destruction within the intestine may also contribute to the disorder [6].

Genetics — Mutations in several genes have been identified in patients with HD [7,8]. HD is a genetically complex disorder caused by variants in multiple rare genes with low penetrance and variable expression [9]. Thus, individuals with multiple pathogenic variants have substantially increased risk compared with those with fewer pathogenic variants. For nonsyndromic forms, long-segment disease tends to be transmitted by autosomal dominant inheritance and short-segment disease often reflects autosomal recessive or multifactorial inheritance [10].

The predominant gene affected is the RET proto-oncogene; mutations in this gene cause a loss of intestinal motor function. More than 20 different mutations in *RET* have been described [11,12]. Coding sequence mutations in *RET* are identified in approximately one-half of all familial cases and approximately one-third of sporadic cases. In one study, *RET* variants were found in 82 percent of patients with total colonic aganglionosis (TCA), compared with 33 percent of those with short-segment disease [13] (see '[Clinical features](#)' below). In addition, certain *RET* polymorphisms are associated with particular phenotypes of HD (short- or long-segment disease) [11]. Most Hirschsprung cases are linked to *RET*, even without an identified coding sequence mutation, suggesting that noncoding variants of this gene play a major role in the disease by causing loss of function of the RET receptor tyrosine kinase that appears to transduce growth and differentiation signals in developing tissues, including those derived from the neural crest. Mouse models have demonstrated that RET protein is necessary for migration, survival, proliferation, and differentiation of the neural crest-derived cells that give rise to the enteric nervous system, and the degree of aganglionosis is proportionate to RET dose [14]. Glial cell line-derived neurotrophic factor (GDNF) and neurturin have been identified as ligands for GDNF receptors and subsequent RET activation, which is essential for normal enteric nervous system development [15]. Mutations in both GDNF and neurturin have also been identified in

patients with HD [7].

The second major gene involved in HD is endothelin receptor *B* ([EDNRB](#)), which encodes a G-protein-coupled receptor [16]. The proteins encoded by *EDNRB* and its ligand endothelin 3 ([EDN3](#)) are both involved in the development of neural crest cells.

The mechanisms underlying the strong association between trisomy 21 (Down syndrome) and HD have not been established. It is likely that multiple mechanisms are involved in this association, including specific *RET* variants and variants in the Down syndrome cell adhesion model ([DSCAM](#)) gene region on chromosome 21 [17,18].

Mutations in other genes have been described in a minority of patients [7]. These genes include [EDN3](#), endothelin-converting enzyme ([ECE1](#)), the gene encoding the Sry-related transcription factor SOX10 ([SOX10](#)), and the paired-like homeobox 2b ([PHOX2B](#)) gene [19,20]. A genome-wide association study also identified an association with neuregulin 1 ([NRG1](#)), a regulator of enteric ganglia precursors [21].

Associated syndromes — HD is associated with chromosomal anomalies, so-called syndromic HD, especially Down syndrome ([table 1](#)). Down syndrome is present in 2 to 16 percent of individuals with HD [22,23]. Conversely, HD occurs in less than 1 percent of individuals with Down syndrome, although the overall risk of HD in Down syndrome is much higher than in the general population [10,24]. (See "[Down syndrome: Clinical features and diagnosis](#)", [section on 'Gastrointestinal abnormalities'](#).)

HD is also associated with several different monogenic syndromes ([table 2](#)):

- Bardet-Biedl syndrome. (See "[Obesity: Genetic contribution and pathophysiology](#)", [section on 'Bardet-Biedl syndrome'](#).)
- Cartilage-hair hypoplasia ([MIM #250250](#)) – This is a rare syndrome characterized by short stature, short limbs with increased carrying angle at the elbow, increased lumbar lordosis, ligamentous laxity, scoliosis, and immunodeficiency. Affected infants often present with enterocolitis. (See "[Cartilage-hair hypoplasia](#)", [section on 'Gastrointestinal abnormalities'](#).)
- Congenital central hypoventilation syndrome (CCHS). The association of CCHS and HD is known as Haddad syndrome. (See "[Congenital central hypoventilation syndrome and other causes of sleep-related hypoventilation in children](#)".)

- Familial dysautonomia (also known as hereditary sensory and autonomic neuropathy type 3, or Riley-Day syndrome). (See ["Hereditary sensory and autonomic neuropathies", section on 'HSAN3 \(Familial dysautonomia\)'](#).)
- Multiple endocrine neoplasia type 2 (MEN2), which is characterized by medullary thyroid cancer and pheochromocytoma, with or without primary hyperparathyroidism. Type 2A is associated with Hirschsprung disease. (See ["Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"](#).)
- Mowat-Wilson syndrome ([MIM #235730](#)) – This is caused by haploinsufficiency of the [ZEB2](#) gene [[25-27](#)]. Approximately 50 percent of individuals with Mowat-Wilson syndrome have HD; other features are distinctive facial characteristics, moderate to severe intellectual disability, genitourinary anomalies, and heart defects.
- Smith-Lemli-Opitz syndrome ([MIM #270400](#)) [[28-31](#)]. (See ["Causes of primary adrenal insufficiency in children", section on 'Defects in cholesterol biochemistry'](#).)
- Waardenburg syndrome – This is an autosomal dominant inherited pigmentary disorder; nearly 100 percent of Waardenburg syndrome type 4 have HD. (See ["The genodermatoses: An overview", section on 'Waardenburg syndrome'](#).)

For trisomy 21, Bardet-Biedl syndrome, and CCHS, *RET* acts as a modifier gene for the Hirschsprung phenotype. Assessment by a clinical geneticist is valuable for all patients with syndromic features or anomalies and also for those with no apparent associated anomalies. (See ["Down syndrome: Clinical features and diagnosis", section on 'Gastrointestinal abnormalities'](#) and ["Disorders of ventilatory control", section on 'Congenital central hypoventilation syndrome'](#) and ["The genodermatoses: An overview", section on 'Waardenburg syndrome'](#).)

CLINICAL FEATURES

Types of aganglionosis — In approximately 80 percent of patients, HD affects the rectosigmoid colon (known as short-segment disease) [[4,10](#)]. In 15 to 20 percent of patients, the aganglionosis extends proximal to the sigmoid colon (known as long-segment disease). In approximately 5 percent, the entire colon is affected (known as total colonic aganglionosis [TCA]), and, in rare cases, the small bowel may also be involved. Outcomes

are generally worse for patients with long-segment as compared with short-segment disease.

Clinical presentation

- **Neonatal** – The majority of patients with HD are diagnosed in the neonatal period. Patients present with symptoms of distal intestinal obstruction: bilious emesis, abdominal distension, and failure to pass meconium or stool [32]. The diagnosis is suggested by a delay in passage of the first meconium. By 48 hours of life, 100 percent of normal full-term neonates will pass meconium [33]. In contrast, 45 to 90 percent of infants with HD will fail to pass meconium within the first 48 hours of life [34-36]. However, passage of stool within the first one to two days of life does not exclude the diagnosis. There may be an explosive expulsion of gas and liquid stool after the digital rectal examination (squirt sign or blast sign), which may relieve the obstruction temporarily [37]. In some infants with HD, the typical clinical features (poor feeding, abdominal distension, and constipation) first become apparent when feeds are switched from breast milk to formula.

Affected infants also may present initially with enterocolitis, a potentially life-threatening illness in which patients have a sepsis-like picture with fever, vomiting, diarrhea, and abdominal distension, which can progress to toxic megacolon. Patients with enterocolitis require stopping oral intake, intravenous fluid resuscitation, intravenous antibiotic therapy including coverage for anaerobic bacteria, rectal irrigations, and, in rare cases, an emergency colostomy. A rare complication of HD is volvulus, which predominantly affects the sigmoid or, less commonly, the transverse colon and cecum. Even less commonly, HD can present with appendiceal perforation [38]. (See ["Emergency complications of Hirschsprung disease"](#).)

- **Postnatal** – Patients with less severe disease (usually because they have short-segment disease) may not be diagnosed until later in infancy or childhood; in approximately 10 percent of individuals, HD is diagnosed after three years of age [39,40]. Such patients typically have a history of chronic constipation and failure to thrive. Although uncommon, HD can be newly diagnosed in adulthood. Patients present with symptoms of abdominal distension and a long history of refractory constipation without fecal incontinence [41,42]. Some of these patients may have "ultrashort-segment Hirschsprung disease" (USSHD), which is described below. (See

['Ultrashort-segment Hirschsprung disease'](#) below and ["Functional constipation in infants, children, and adolescents: Clinical features and diagnosis".](#))

Associated congenital anomalies — Approximately 20 to 25 percent of patients with HD have associated congenital anomalies ([figure 1](#)), often but not always in association with one of the syndromes described above.

- **Genitourinary anomalies** – Congenital anomalies of the kidney and urinary tract (CAKUT), including hydronephrosis and renal hypoplasia, are particularly common [[22,43,44](#)]. This association is not explained by a simple relationship with RET or GDNF, but these genes could be involved as disease modifiers. In a report of 106 HD patients who underwent routine ultrasonographic screening, CAKUT were found in approximately 20 percent of individuals with nonsyndromic HD and 40 percent of those with syndromic HD [[22](#)]. Because of this high frequency, the authors of that report suggested that infants with HD undergo routine ultrasonographic screening for urinary system malformations. (See ["Overview of congenital anomalies of the kidney and urinary tract \(CAKUT\)"](#) and ["Evaluation of congenital anomalies of the kidney and urinary tract \(CAKUT\)"](#).)
- **Visual and hearing impairment** – In one case series, ophthalmologic abnormalities were found in approximately 40 percent of individuals with HD. Most were refractive errors (hyperopia, astigmatism, or myopia), but visual impairment was present in 9.4 percent [[22](#)]. Hearing impairment was found in approximately 5 percent of individuals with HD, approximately three times the rate in the general population. The authors suggest routine screening for hearing impairment, using protocols for infants at increased risk. (See ["Screening the newborn for hearing loss"](#) and ["Hearing loss in children: Screening and evaluation"](#).)
- **Congenital heart disease** – Congenital heart disease is found in approximately 50 percent of individuals with syndromic HD (usually Down syndrome) [[22](#)] but is unusual in patients without an associated syndrome [[10](#)].
- **Anorectal malformations** – HD may also occur in association with anorectal malformations; the possibility of HD should be considered in patients with anorectal malformations who develop constipation that does not respond to standard treatment and in those with other symptoms suggestive of HD [[45](#)].

EVALUATION

HD should be suspected in patients with the clinical symptoms discussed above. A high index of suspicion is appropriate for neonates and infants with a predisposing condition, such as Down syndrome, or for those with a family history of HD ([algorithm 1](#)).

Indications for testing

Suspected Hirschsprung disease in neonates

- **High suspicion** – A high suspicion for HD is suggested by the following characteristics in infants <6 months of age:
 - Symptoms of intestinal obstruction, including bilious emesis, abdominal distension, and failure to pass stool
 - Failure to pass meconium within 48 hours of birth
 - Constipation and any of the following:
 - Trisomy 21 (Down syndrome) or other condition known to be associated with HD
 - Family history of HD
 - Physical examination suggestive of HD (abdominal distension, tight anal sphincter, narrowed rectum, or squirt sign on digital examination) (see '[Clinical features](#)' above)

Such infants should have an urgent full evaluation, usually consisting of a contrast enema and rectal suction biopsy ([algorithm 1](#)). (See '[Diagnostic testing](#)' below and '[Rectal biopsy](#)' below.)

- **Moderate suspicion** – A moderate level of suspicion for HD is warranted for neonates with a well-documented, moderate delay in passing meconium (>48 hours but <72 hours) but no other symptoms (no abdominal distension, vomiting, or feeding problems).

Practice varies regarding the management of these infants. They should undergo a careful physical examination and exclusion of other causes of delayed passage of meconium, including anorectal malformations ([table 3](#)) (see "[Constipation in infants and children: Evaluation](#)", [section on 'Physical examination'](#)"). They should also be

closely observed and evaluated promptly for HD if they develop symptoms of constipation or abdominal distension.

Anorectal manometry is a useful screening test in patients with mild to moderate symptoms (see ['Anorectal manometry'](#) below). It would also be reasonable to perform a contrast enema and suction rectal biopsy in such infants, particularly if close observation cannot be assured. An urgent evaluation is essential if the infant develops symptoms of obstruction or enterocolitis.

Suspected enterocolitis — Urgent evaluation for Hirschsprung-associated enterocolitis (HAEC) is indicated for any neonate or infant who presents with fever, vomiting, abdominal distension, and explosive diarrhea and has known or suspected HD. This includes infants who have undergone surgical repair for HD or those with risk factors such as Down syndrome or a family history of HD. Other concerning symptoms include lethargy or obstipation ([table 4](#)) [46]. HAEC seldom occurs in neonates except when the diagnosis of HD is missed or delayed. The diagnosis of HD or HAEC can be missed in an infant who has an atypical subacute presentation of chronic diarrhea and failure to grow [47].

All such patients should have a rectal examination, performed either with a finger (digital) or with a small-diameter anal dilator; an explosive release of gas and liquid stool during this examination supports a diagnosis of HAEC. The evaluation should also include an abdominal radiograph. The possibility of HAEC is supported by signs of ileus, including air-fluid levels and dilated bowel. A contrast enema should **not** be performed if HAEC is suspected, because of the risk of bacterial translocation with subsequent septicemia and/or intestinal perforation.

Evaluation, diagnosis, and management of HAEC are discussed separately. (See ["Emergency complications of Hirschsprung disease", section on 'Enterocolitis'.](#))

Chronic refractory constipation — For older infants and toddlers with chronic refractory constipation (ages three months to three years), the level of suspicion for HD is guided by the history and physical examination:

- For those with failure to thrive and other signs suggestive of HD on physical examination (abdominal distension, narrowed rectum without stool present, tight anal sphincter, or squirt sign on examination), a moderate level of suspicion for HD is warranted. These individuals should be evaluated for HD, but the timing and

sequence of diagnostic testing is elective. In this group, anorectal manometry is an excellent screening test if it is available. A normal anorectal inhibitory reflex excludes HD.

- For those with **no** symptoms or signs suggestive of HD, a lesser level of suspicion for HD is warranted. For such patients, it is reasonable to evaluate with a plain radiograph and base further testing on the results. (See '[Abdominal radiograph](#)' below.)

Diagnostic testing — Rectal biopsy is the gold standard for diagnosis. Before proceeding to rectal biopsy, we typically perform noninvasive tests to support the likely diagnosis, contrast enema, or anorectal manometry. Each of these procedures has advantages and disadvantages related to availability, technical expertise, radiation exposure, and invasiveness [48]. The diagnostic steps depend on the level of suspicion for HD, age of the child, whether there is concern about HAEC (which requires emergency management), and on the available resources and institutional/clinician preference ([algorithm 1](#)).

In our practice, we generally perform a contrast enema rather than suction biopsy as the initial diagnostic procedure. If a clear transition zone is seen on [barium](#) enema, the study is virtually pathognomonic of HD and helps the surgeon plan the operative approach. If a transition zone is not seen, HD cannot be entirely excluded. We always confirm the diagnosis by rectal biopsy even when the barium enema shows typical features of HD.

Some providers start the evaluation with anorectal manometry, followed by rectal suction biopsy if the findings are abnormal.

Contrast enema — In infants with suspected HD, a contrast enema can support the diagnosis of HD; it is performed without stool cleanout ("unprepped"). However, this test is not sufficient to exclude the diagnosis of HD, especially in newborns or other individuals with a high clinical suspicion for the disease [49,50]. The rectum and colon may look relatively normal in cases of long-segment or total colonic HD. A contrast enema is also useful for presurgical planning because it may help the surgeon to localize the transition zone and determine the length of the aganglionic segment [48], although the location of the transition zone on imaging does not always match its true pathologic location [51].

The presence of a "transition zone," which represents the change from the normal caliber/narrowed rectum (aganglionic segment) to the dilated colon proximal to the

aganglionic region, is virtually pathognomonic of HD ([image 1](#)). Despite this high degree of certainty, we always confirm the diagnosis by rectal biopsy before surgery. The transition zone usually is in the rectosigmoid area and is seen best in the early lateral and oblique views. In patients with total colonic involvement, the entire colon may appear relatively normal, but dilated loops of distal small bowel may be visible [\[52\]](#). If a transition zone is not clearly detected, a follow-up postevacuation film 24 hours later may reveal residual retained contrast in the colon, which is suggestive of the diagnosis [\[53\]](#). The rectosigmoid index (RSI), the ratio between the diameter of the rectum and the sigmoid colon, is typically >1 in normal children. Reversal of this ratio, although less often noted than a transition zone, is a useful sign of HD in infants and older children [\[54,55\]](#).

The use of contrast enema for diagnosis of HD is limited by false-negative results, which render this test less sensitive than rectal suction biopsy and anorectal manometry for the diagnosis of HD ([table 5](#)) [\[48,56\]](#). As an example, a digital rectal examination within a few days prior to the contrast enema may dilate the rectum and cause a false-negative result. Similarly, classic radiographic findings such as inversion of the RSI may not be evident in studies performed in the early newborn period or in premature infants [\[57\]](#). Therefore, a normal contrast enema is not sufficient to exclude the diagnosis of HD in a neonate with a high clinical suspicion of disease. In a single-center retrospective study of newborns who were clinically suspected to have HD, 32 percent of those who had inconclusive findings on contrast enema were ultimately diagnosed with HD, compared with 2.5 percent of those with negative findings on contrast enema [\[49\]](#). However, in patients with a low clinical suspicion of HD, a contrast enema provides good evidence to exclude the diagnosis. This was shown in a study that compared 50 children who presented with constipation and were diagnosed with HD with a concurrent cohort of 50 patients with idiopathic constipation [\[58\]](#). Significantly more patients with HD experienced delayed passage of meconium, abdominal distension, and vomiting and had a transition zone identified on a contrast enema. The presence of at least one of these findings was identified in every patient diagnosed with HD compared with 64 percent of patients with idiopathic constipation. Thus, the authors suggest that rectal biopsy may be avoided in children with constipation who lack all of these clinical and radiologic features.

Anorectal manometry — Anorectal manometry sometimes is a very useful aid in the diagnosis and is especially helpful in patients with ultrashort-segment Hirschsprung disease (USSHD). It is helpful as a screening test because a clearly normal study

demonstrating relaxation of the internal anal sphincter with distension of the rectum excludes the diagnosis of HD. Lack of relaxation of the internal anal sphincter with balloon rectal distension is suggestive of HD, but false positives can occur. Anorectal manometry has a positive predictive value that is reported to be 75 to 95 percent but is less accurate in infants younger than one month of age and those with longstanding chronic constipation [56,59,60]. (See "[Constipation in infants and children: Evaluation](#)", section on 'Anorectal manometry'.)

Rectal biopsy — A suction rectal biopsy can be done at the bedside or in an ambulatory setting without the need for general anesthesia. A biopsy should be taken 2 cm above the level of the dentate line to avoid the 1 to 2 cm zone of physiologic hypoganglionosis or aganglionosis that is normally present. A second biopsy should be taken proximal to the first one. Although adequate tissue is obtained for analysis in the majority of infants and toddlers, in children above age three years, the rate of adequate tissue declines progressively from 88 percent to 70 and 45 percent (in adolescents) [61-63]. Repeat suction biopsies, grasp-forceps biopsies, or full-thickness biopsies under general anesthesia can be performed if the initial biopsy is nondiagnostic (ie, if insufficient tissue is obtained).

The diagnosis of HD is established if ganglion cells are absent in the rectal biopsy, provided that the tissue sample is adequate ([picture 1](#)). Supportive findings include the presence of hypertrophic nerve fibers, increased acetylcholinesterase activity or staining in the muscularis mucosae, and decreased or absent calretinin-immunoreactive fibers in the lamina propria [64-67]. Excessively thickened nerve fibers may not appear until after eight weeks of age [68]. (See '[Diagnosis](#)' below.)

A normal rectal biopsy virtually excludes HD, provided that the biopsy samples are obtained from the correct site and contain at least a small amount of muscularis mucosae. Thus, a rectal suction biopsy is more sensitive and specific than contrast enema and anorectal manometry for the diagnosis of HD for children up to three years of age ([table 5](#)) [48,56].

Abdominal radiograph — A plain abdominal radiograph is not helpful in excluding the diagnosis of HD, except perhaps for patients in whom there is a low suspicion of disease (eg, children with moderate refractory constipation but no other clinical features of HD and a normal anorectal examination). If a plain radiograph is performed, the possibility of HD is suggested by signs of distal intestinal obstruction, ie, decreased or absent air in the rectum

and dilated bowel loops proximal to the aganglionic region. Occasionally, careful review of the plain radiographs may reveal the transition zone even when it is not visible on the contrast enema [69].

DIAGNOSIS

HD is suspected based on clinical features described above, usually supported by contrast enema or anorectal manometry. (See '[Contrast enema](#)' above and '[Anorectal manometry](#)' above.)

The diagnosis is established by rectal biopsy (a rectal suction biopsy and/or a full-thickness biopsy). **Absence of ganglia** on the suction biopsy confirms the diagnosis of HD, provided that the sample is adequate, meaning that the biopsies were obtained from the correct site and contain at least a small amount of muscularis mucosae. If ganglia are seen in an appropriately performed suction biopsy, HD is virtually excluded. (See '[Rectal biopsy](#)' above.)

DIFFERENTIAL DIAGNOSIS

Other disorders that may present with intestinal obstruction in a newborn infant include:

- Gastrointestinal malformations, including intestinal stenosis or atresia, duplication cysts, or malrotation. (See '[Intestinal atresia](#)' and '[Intestinal malrotation in children](#)'.)
- Meconium ileus due to cystic fibrosis. (See '[Cystic fibrosis: Overview of gastrointestinal disease](#)', section on 'Meconium ileus'.)
- Multiple endocrine neoplasia type 2 (MEN2). Type 2A is associated with Hirschsprung disease, whereas type 2B may be associated with ganglioneuromatosis, skeletal deformations, and Marfanoid habitus. (See '[Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2](#)'.)
- Disorders causing chronic intestinal pseudo-obstruction, including intestinal neuronal dysplasia. (See '[Chronic intestinal pseudo-obstruction: Etiology, clinical manifestations, and diagnosis](#)', section on 'Genetic' and '[Functional constipation in infants, children, and adolescents: Clinical features and diagnosis](#)', section on 'Other

[causes'.\)](#)

- Meconium plug syndrome, a condition that occurs in up to 1:500 newborns and is due to colonic dysmotility or abnormal consistency of meconium, leading to obstipation in the newborn. A contrast enema is both diagnostic and therapeutic. However, approximately 15 percent of infants with meconium plug syndrome also have HD, so a full diagnostic evaluation for HD, including rectal suction biopsy, is warranted [\[70\]](#).
- Small left colon syndrome, which typically occurs in infants of diabetic mothers and appears to be due to transient left colon dysmotility, leading to delayed passage of stool. A contrast enema makes the diagnosis, showing a contracted left colon, and the problem usually resolves on its own after a few days. These neonates should undergo rectal biopsy to ensure that they do not have HD.

These disorders can be distinguished from HD by their clinical features and the presence of ganglia on a rectal suction biopsy.

In older infants and children, the main consideration in the differential diagnosis is functional constipation. Other possibilities include anorectal anomalies, internal anal sphincter achalasia, hypothyroidism, and chronic intestinal pseudo-obstruction (see ["Functional constipation in infants, children, and adolescents: Clinical features and diagnosis"](#)). Classical HD also should be distinguished from ultrashort-segment Hirschsprung disease (USSHD), as discussed below. (See ["Ultrashort-segment Hirschsprung disease"](#) below.)

MANAGEMENT

Surgical correction — The mainstay of treatment is surgery. The goals are to resect the affected segment of the rectum and colon, bring the normal ganglionic bowel down to an anastomosis to the distal rectum close to the anus, and preserve internal anal sphincter function. Many surgical techniques have been developed. The choice among them usually is based upon surgeon preference since the overall complication rates and long-term results are similar [\[37,71\]](#).

The traditional operation was an abdominoperineal pull-through in two or three stages, in

which patients initially underwent a diverting colostomy (to allow the dilated bowel to decompress) with definitive repair performed later. However, most centers now perform the procedure in one stage, an approach that does not appear to increase complication rates [37,72-74]. Laparoscopic-assisted and transanal repairs are commonplace and are now preferred over the open procedures in most centers. The outcome seems to be equivalent to the traditional abdominoperineal pull-through, with the added benefits of earlier resumption of full feeds, less pain, shorter hospitalization, and less conspicuous scars [75-78]. In a systematic review and meta-analysis comparing totally transanal, endorectal, and laparoscopic-assisted pull-through, operative time was found to be shorter for the transanal procedure [79]. However, the incidence of serious complications such as enterocolitis, incontinence, and chronic constipation did not differ between the two procedures. The frequency of postoperative internal anal sphincter defects identified by endosonography was also higher in patients undergoing a transanal approach (69 versus 19 percent). These findings should be confirmed with data from other centers and with different lengths of follow-up to fully understand the implications of this operative approach.

Patients with ultrashort-segment Hirschsprung disease (USSHD) may not require a pull-through operation. (See '[Ultrashort-segment Hirschsprung disease](#)' below.)

Treatment of the emergency complications of HD, including acute bowel obstruction, enterocolitis, and volvulus, is discussed separately. (See "[Emergency complications of Hirschsprung disease](#)".)

Further evaluation for associated anomalies — The clinician should be alert for signs or symptoms of congenital anomalies in patients with suspected HD. For all patients with HD, and particularly those with syndromic HD, genitourinary anomalies, hearing impairment, and visual impairment are common ([figure 1](#)). In light of the high rate of urinary tract anomalies in both nonsyndromic (20 percent) and syndromic (40 percent) HD, some experts recommend ultrasonographic screening for urinary system malformations in all patients with HD [22], but practice varies. (See '[Associated congenital anomalies](#)' above.)

Assessment by a clinical geneticist is valuable for all patients with syndromic features or anomalies and also for those with no apparent associated anomalies. Genetic screening for multiple endocrine neoplasia type 2A (MEN2A) may be offered to the families of infants with HD and particularly for those with a family history of MEN2 or related neoplasms in

first-degree relatives. (See ['Associated syndromes'](#) above and ['Associated congenital anomalies'](#) above and ['Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2', section on 'Genetic screening'](#).)

ULTRASHORT-SEGMENT HIRSCHSPRUNG DISEASE

The term "ultrashort-segment Hirschsprung disease" (USSHD) is sometimes used to describe a form characterized by a very short segment of aganglionosis extending 2 to 4 cm proximal to the internal anal sphincter. Most experts agree that this form exists, although there is some controversy on this point.

The clinical picture is similar to the classical short-segment HD (which involves most or all of the rectum and part of the sigmoid colon), except that the degree of constipation may be less severe and the complications of growth retardation and enterocolitis are less likely to develop. On contrast enema, the rectum may be dilated down to the internal sphincter and there may not be a visible transition zone. If anorectal manometry is performed, the anorectal inhibitory reflex is absent, as it is in the other forms of HD. The lack of anorectal relaxation is the physiologic basis for the clinical features.

The diagnosis of USSHD is established by taking two biopsies:

- A biopsy taken just proximal to the dentate line that shows aganglionosis – This distinguishes USSHD from internal anal sphincter achalasia (which has similar findings on anorectal manometry, but in achalasia, ganglion cells are present). (See ['Functional constipation in infants, children, and adolescents: Clinical features and diagnosis', section on 'Internal anal sphincter achalasia'](#).)
- A biopsy taken approximately 4 cm above the internal sphincter that shows normal ganglion cells – This biopsy distinguishes USSHD from classical HD, in which ganglion cells would be absent.

It is important to distinguish patients with USSHD from those with typical HD because patients with USSHD may not require a pull-through operation. Some patients with USSHD respond to bowel management with diet, stool softeners, and laxatives. Others respond to botulinum toxin injections. If these measures fail, a myomectomy should be considered, removing a 0.5 to 1.0 cm-wide strip of inner circular muscle in the posterior midline, from

the level of the internal anal sphincter to the level of the normal ganglionated bowel.

OUTCOME

Although many patients achieve normal or near-normal bowel function, abnormalities of bowel function are common after definitive surgery for HD. Overall quality of life (QOL) is generally good, even when bowel function is not normal [80-87]. The most common long-term complications are constipation, fecal incontinence, and enterocolitis. Fecal incontinence has the greatest impact on QOL. Patients with trisomy 21 or other syndromes are more likely to have constipation or incontinence [88]. Total colonic aganglionosis (TCA) has a much higher rate of complications and mortality before and after definitive treatment compared with the more common forms of HD, in which a smaller portion of the colon is affected [89]. TCA also has a much higher risk for enterocolitis and poor functional results, including chronic diarrhea and fecal incontinence after surgery. These symptoms are often associated with severe skin irritation, excoriation, and frank breakdown in the diaper area. Some patients, especially those with residual aganglionosis or stricture formation, may benefit from a redo pull-through procedure [90]. In general, bowel function tends to improve over time [91].

Constipation — Constipation or persistent obstructive symptoms, which include vomiting, bloating, borborygmi, abdominal distension, and severe constipation, occur in 10 to 30 percent of patients after operative repair for HD [92]. This can be caused by mechanical obstruction (eg, stricture), persistent or acquired aganglionosis, a colonic motility disorder (eg, intestinal neuronal dysplasia), increased internal anal sphincter tone, or nonspecific colonic dysmotility/stool-withholding behavior [93]. The diagnostic evaluation typically includes a radiographic contrast study to evaluate for stricture, rectal suction biopsy to evaluate for persistent aganglionosis, and an assessment of motility (eg, radiopaque marker study).

Guidelines for the management of postoperative obstructive symptoms in children with HD have been published by the American Pediatric Surgical Association [92]. If increased internal anal sphincter tone is suspected, a trial of botulinum toxin injection may be helpful (algorithm 2) [94,95]. In many cases, obstructive symptoms improve or resolve with time [83].

Enterocolitis — Despite surgical repair, Hirschsprung-associated enterocolitis (HAEC) is a major cause of postoperative morbidity and occasional mortality, with postoperative incidence rates as high as 45 percent [46,88,96-98]. It usually occurs within the first year after surgical repair and rarely occurs more than five years postoperatively [97,99]. HAEC is also more common in long-segment disease, especially TCA. Use of home rectal irrigations may reduce the need for hospitalization for HAEC [100].

The risk for HAEC appears to be increased in patients with an anastomotic stricture, suggesting that intestinal stasis may have a role in the etiology [97]. HAEC is more likely to develop after the pull-through operation if there is histologic evidence of inflammation in the resected colon [101]. The risk is also increased in patients with long-segment disease, particularly for patients with TCA [96,102,103]; such patients also have increased risks for perianal excoriations, electrolyte imbalance, and anastomotic leak as compared with patients with rectosigmoid disease [104]. The risk for these problems tends to improve with time after surgery. A few reports have suggested an association between HAEC and subsequent development of Crohn disease [105,106]. The risk factors, clinical presentation, and management of HAEC are discussed in greater detail separately. (See "[Emergency complications of Hirschsprung disease](#)", [section on 'Enterocolitis'](#).)

Incontinence — Diarrhea and incontinence are common during the early postoperative period, but they seem to improve with time [107]. Loss of water-absorptive surface area from colonic resection and anal sphincter dysfunction are likely etiologic factors. The latter may be due to damage to the anal canal and internal sphincter during the pull-through operation [108,109]. Improvement of bowel function occurs in the majority of patients with frequency of stools and continence improving with age [76,80,96,102,107,110,111]. In most patients, there is a rapid decrease in stool frequency during the first six months postoperatively, with a slower decline over the next several years [76].

Long-term follow-up reveals that approximately 75 to 95 percent of patients achieve a stool frequency of five or fewer stools per day [102,110,111]. Some patients may have persistent problems with constipation and fecal incontinence [102,110-113]. In one long-term study, 42 percent of patients had occasional soiling and 12 percent had frequent soiling [88].

For patients with fecal incontinence following pull-through surgery, anorectal manometry and contrast enema distinguish the underlying cause and guide management [114]:

- Incontinence – Indicated by poor anorectal sensation or sphincter weakness on

anorectal manometry. For these patients, management may include dietary modification and bowel management and/or more invasive options (eg, diverting ostomy).

- Pseudoincontinence – Indicated by fecal soiling with normal anorectal sensation and sphincter function on anorectal manometry. The cause can be further categorized based on the results of a contrast enema, with or without colonic motility studies:
 - Fecal impaction with overflow leakage – Suggested by dilated neo-rectum; these patients are managed with a conventional constipation regimen
 - Hypermotility – Suggested by normal-caliber neo-rectum; these patients are managed with bulking agents and antimotility medications

Over time, most patients with pseudoincontinence will improve. However, most patients with Down syndrome and HD continue to have disturbances of bowel function (soiling, recurrent enterocolitis) over the long term and some resort to a permanent colostomy [88,115]. For most patients with HD, the disease-specific QOL tends to improve as time passes; those with total colonic HD are more likely to report psychosocial adjustment problems [82,116].

Urologic and sexual outcomes — Urologic and sexual complications, specifically urinary incontinence and erectile dysfunction, have been reported after surgery for HD [117-119]. A study suggests that these problems are no more common than in matched controls [117]. However, caution is appropriate since urinary and sexual dysfunction are known to occur after other types of pelvic surgery and because these problems may not be recognized until years later. One long-term follow-up study found a difference in fertility and sexual QOL between adult men and women [120]. Most men had normal fertility and sexual QOL after surgery for HD, whereas fertility and sexual QOL were often reduced in women. Dyspareunia was one of the outcomes that accounted for the reduced sexual QOL. As is true for overall QOL, poor bowel function was associated with these problems. Prospective documentation of urologic and sexual outcomes in all Hirschsprung cases has been suggested [118].

INFORMATION FOR PATIENTS

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

- Basics topics (see ["Patient education: Hirschsprung disease \(The Basics\)"](#))

SUMMARY AND RECOMMENDATIONS

- **Disease spectrum** – Hirschsprung disease (HD) is caused by congenital absence of ganglion cells in the distal rectum and extends proximally into the colon for a variable distance. It affects the rectum and part of the sigmoid colon in approximately 80 percent of patients, but it also can involve more proximal segments, the entire colon, or (in rare cases) most of the small bowel. (See ["Types of aganglionosis"](#) above.)
- **Associated syndromes and anomalies** – There is an increased risk for HD among patients with trisomy 21 and several other genetic syndromes ([table 2](#)). Assessment by a clinical geneticist is valuable for all patients with syndromic features or anomalies, as well as for those with no apparent associated anomalies. (See ["Associated syndromes"](#) above.)

For all patients with HD, and particularly those with syndromic HD, genitourinary anomalies, hearing impairment, and visual impairment are common ([figure 1](#)). Congenital heart disease is common among those with syndromic HD. The clinician should be alert for signs or symptoms of congenital anomalies in patients with suspected HD. (See ["Associated congenital anomalies"](#) above.)

- **Clinical presentation** – (See ["Clinical presentation"](#) above.)

- The majority of patients with HD are diagnosed in the neonatal period when they present with symptoms of distal intestinal obstruction, including bilious emesis, abdominal distension, and failure to pass stool. A high index of suspicion is appropriate for infants with a predisposing condition such as Down syndrome or for those with a family history of HD.
- Occasionally, affected infants may present with Hirschsprung-associated enterocolitis (HAEC), a potentially life-threatening illness in which patients have a sepsis-like picture with fever, vomiting, diarrhea, and abdominal distension, which can progress to toxic megacolon. (See ["Emergency complications of Hirschsprung disease", section on 'Enterocolitis'.](#))
- Patients with less severe (short-segment or ultrashort-segment) HD may not be diagnosed until later in infancy or childhood. Such patients typically have a history of chronic constipation and failure to thrive. Patients with ultrashort-segment HD may not require a pull-through operation. (See ["Ultrashort-segment Hirschsprung disease"](#) above.)
- **Indications for evaluation in a neonate** – An urgent full evaluation for HD is appropriate for newborns or young infants (<6 months old) with the following features (see ["Suspected Hirschsprung disease in neonates"](#) above):
 - Symptoms of obstruction (bilious emesis, abdominal distension, and failure to pass stool)
 - Failure to pass meconium within 48 hours of birth
 - Constipation and trisomy 21 or other condition known to be associated with HD, or a family history of HD
 - Constipation and physical examination suggestive of HD (tight anal sphincter; narrowed, empty rectum; or squirt sign on digital examination)
- **Evaluation and diagnosis** – Definitive diagnosis of HD is made by rectal biopsy, which may be supported by findings on abdominal radiographs, contrast enema, or anorectal manometry. The diagnostic steps depend on the level of suspicion for HD, whether there is concern about enterocolitis (HAEC, which requires emergency management), age of the child, and on the available resources and institutional/clinician preference ([algorithm 1](#)). (See ["Evaluation"](#) above and ["Diagnosis"](#) above.)

- **Initial management** – The treatment for HD is surgical resection of the aganglionic segment of bowel. The normal ganglionic bowel is brought down and anastomosed just proximal to the anus with care to avoid damage to the internal anal sphincter. (See '[Management](#)' above.)
- **Outcomes** – Abnormalities of bowel function are common after definitive surgery for HD, although overall quality of life (QOL) is generally good. The most common long-term complications are constipation and fecal incontinence. Postoperative enterocolitis may also occur and is a medical emergency. (See '[Outcome](#)' above and '[Emergency complications of Hirschsprung disease](#)'.)

REFERENCES

1. [Suita S, Taguchi T, Ieiri S, Nakatsuji T. Hirschsprung's disease in Japan: analysis of 3852 patients based on a nationwide survey in 30 years. J Pediatr Surg 2005; 40:197.](#)
2. [Best KE, Addor MC, Arriola L, et al. Hirschsprung's disease prevalence in Europe: a register based study. Birth Defects Res A Clin Mol Teratol 2014; 100:695.](#)
3. [Ieiri S, Suita S, Nakatsuji T, et al. Total colonic aganglionosis with or without small bowel involvement: a 30-year retrospective nationwide survey in Japan. J Pediatr Surg 2008; 43:2226.](#)
4. [Badner JA, Sieber WK, Garver KL, Chakravarti A. A genetic study of Hirschsprung disease. Am J Hum Genet 1990; 46:568.](#)
5. [Fu M, Tam PK, Sham MH, Lui VC. Embryonic development of the ganglion plexuses and the concentric layer structure of human gut: a topographical study. Anat Embryol \(Berl\) 2004; 208:33.](#)
6. [McKeown SJ, Stamp L, Hao MM, Young HM. Hirschsprung disease: a developmental disorder of the enteric nervous system. Wiley Interdiscip Rev Dev Biol 2013; 2:113.](#)
7. [Goldstein AM, Hofstra RM, Burns AJ. Building a brain in the gut: development of the enteric nervous system. Clin Genet 2013; 83:307.](#)
8. [Amiel J, Sproat-Emison E, Garcia-Barcelo M, et al. Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet 2008; 45:1.](#)
9. [Tilghman JM, Ling AY, Turner TN, et al. Molecular Genetic Anatomy and Risk Profile of Hirschsprung's Disease. N Engl J Med 2019; 380:1421.](#)

10. Parisi MA. Hirschsprung Disease Overview. 2002 Jul 12 [Updated 2015 Oct 1]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1439/> (Accessed on May 01, 2019).
11. [Fitze G, Cramer J, Ziegler A, et al. Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease. Lancet 2002; 359:1200.](#)
12. [Kim JH, Yoon KO, Kim JK, et al. Novel mutations of RET gene in Korean patients with sporadic Hirschsprung's disease. J Pediatr Surg 2006; 41:1250.](#)
13. [Moore SW, Zaahl M. Clinical and genetic differences in total colonic aganglionosis in Hirschsprung's disease. J Pediatr Surg 2009; 44:1899.](#)
14. [Uesaka T, Nagashimada M, Yonemura S, Enomoto H. Diminished Ret expression compromises neuronal survival in the colon and causes intestinal aganglionosis in mice. J Clin Invest 2008; 118:1890.](#)
15. [Uesaka T, Jain S, Yonemura S, et al. Conditional ablation of GFRalpha1 in postmigratory enteric neurons triggers unconventional neuronal death in the colon and causes a Hirschsprung's disease phenotype. Development 2007; 134:2171.](#)
16. [Sánchez-Mejías A, Fernández RM, López-Alonso M, et al. New roles of EDNRB and EDN3 in the pathogenesis of Hirschsprung disease. Genet Med 2010; 12:39.](#)
17. [Jannot AS, Pelet A, Henrion-Caude A, et al. Chromosome 21 scan in Down syndrome reveals DSCAM as a predisposing locus in Hirschsprung disease. PLoS One 2013; 8:e62519.](#)
18. [Moore SW. Advances in understanding the association between Down syndrome and Hirschsprung disease \(DS-HSCR\). Pediatr Surg Int 2018; 34:1127.](#)
19. [Martucciello G, Ceccherini I, Lerone M, Jasonni V. Pathogenesis of Hirschsprung's disease. J Pediatr Surg 2000; 35:1017.](#)
20. [Bajaj R, Smith J, Trochet D, et al. Congenital central hypoventilation syndrome and Hirschsprung's disease in an extremely preterm infant. Pediatrics 2005; 115:e737.](#)
21. [Garcia-Barcelo MM, Tang CS, Ngan ES, et al. Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease. Proc Natl Acad Sci U S A 2009; 106:2694.](#)
22. [Pini Prato A, Rossi V, Mosconi M, et al. A prospective observational study of associated](#)

- [anomalies in Hirschsprung's disease. Orphanet J Rare Dis 2013; 8:184.](#)
23. [Menezes M, Puri P. Long-term clinical outcome in patients with Hirschsprung's disease and associated Down's syndrome. J Pediatr Surg 2005; 40:810.](#)
 24. [Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics 2011; 128:393.](#)
 25. [Bonnard A, Zeidan S, Degas V, et al. Outcomes of Hirschsprung's disease associated with Mowat-Wilson syndrome. J Pediatr Surg 2009; 44:587.](#)
 26. [Saunders CJ, Zhao W, Ardinger HH. Comprehensive ZEB2 gene analysis for Mowat-Wilson syndrome in a North American cohort: a suggested approach to molecular diagnostics. Am J Med Genet A 2009; 149A:2527.](#)
 27. Adam MP, Bean LJH, Miller VR. Mowat-Wilson Syndrome (Hirschsprung disease-mental retardation syndrome). Gene Reviews 2008. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1412/>.
 28. [Parisi MA, Kapur RP. Genetics of Hirschsprung disease. Curr Opin Pediatr 2000; 12:610.](#)
 29. [Flori E, Girodon E, Samama B, et al. Trisomy 7 mosaicism, maternal uniparental heterodisomy 7 and Hirschsprung's disease in a child with Silver-Russell syndrome. Eur J Hum Genet 2005; 13:1013.](#)
 30. [Mueller C, Patel S, Irons M, et al. Normal cognition and behavior in a Smith-Lemli-Opitz syndrome patient who presented with Hirschsprung disease. Am J Med Genet A 2003; 123A:100.](#)
 31. [de Pontual L, Pelet A, Clement-Ziza M, et al. Epistatic interactions with a common hypomorphic RET allele in syndromic Hirschsprung disease. Hum Mutat 2007; 28:790.](#)
 32. [Khan AR, Vujanic GM, Huddart S. The constipated child: how likely is Hirschsprung's disease? Pediatr Surg Int 2003; 19:439.](#)
 33. [Clark DA. Times of first void and first stool in 500 newborns. Pediatrics 1977; 60:457.](#)
 34. [Klein MD, Coran AG, Wesley JR, Drongowski RA. Hirschsprung's disease in the newborn. J Pediatr Surg 1984; 19:370.](#)
 35. [Singh SJ, Croaker GD, Manglick P, et al. Hirschsprung's disease: the Australian Paediatric Surveillance Unit's experience. Pediatr Surg Int 2003; 19:247.](#)
 36. [Bradnock TJ, Knight M, Kenny S, et al. Hirschsprung's disease in the UK and Ireland: incidence and anomalies. Arch Dis Child 2017; 102:722.](#)

37. [Lall A, Gupta DK, Bajpai M. Neonatal Hirschsprung's disease. Indian J Pediatr 2000; 67:583.](#)
38. [Sarioğlu A, Tanyel FC, Büyükpamukçu N, Hiçsönmez A. Appendiceal perforation: a potentially lethal initial mode of presentation of Hirschsprung's disease. J Pediatr Surg 1997; 32:123.](#)
39. [Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2006; 43:e1.](#)
40. [Arshad A, Powell C, Tighe MP. Hirschsprung's disease. BMJ 2012; 345:e5521.](#)
41. [Wheatley MJ, Wesley JR, Coran AG, Polley TZ Jr. Hirschsprung's disease in adolescents and adults. Dis Colon Rectum 1990; 33:622.](#)
42. [Crocker NL, Messmer JM. Adult Hirschsprung's disease. Clin Radiol 1991; 44:257.](#)
43. [Sarioglu A, Tanyel FC, Büyükpamukçu N, Hiçsönmez A. Hirschsprung-associated congenital anomalies. Eur J Pediatr Surg 1997; 7:331.](#)
44. [Pini Prato A, Musso M, Ceccherini I, et al. Hirschsprung disease and congenital anomalies of the kidney and urinary tract \(CAKUT\): a novel syndromic association. Medicine \(Baltimore\) 2009; 88:83.](#)
45. [Hofmann AD, Puri P. Association of Hirschsprung's disease and anorectal malformation: a systematic review. Pediatr Surg Int 2013; 29:913.](#)
46. [Gosain A, Frykman PK, Cowles RA, et al. Guidelines for the diagnosis and management of Hirschsprung-associated enterocolitis. Pediatr Surg Int 2017; 33:517.](#)
47. [Nofech-Mozes Y, Rachmel A, Schonfeld T, et al. Difficulties in making the diagnosis of Hirschsprung disease in early infancy. J Paediatr Child Health 2004; 40:716.](#)
48. [De Lorijn F, Reitsma JB, Voskuil WP, et al. Diagnosis of Hirschsprung's disease: a prospective, comparative accuracy study of common tests. J Pediatr 2005; 146:787.](#)
49. [Putnam LR, John SD, Greenfield SA, et al. The utility of the contrast enema in neonates with suspected Hirschsprung disease. J Pediatr Surg 2015; 50:963.](#)
50. [Carroll AG, Kavanagh RG, Ni Leidhin C, et al. Comparative Effectiveness of Imaging Modalities for the Diagnosis of Intestinal Obstruction in Neonates and Infants:: A Critically Appraised Topic. Acad Radiol 2016; 23:559.](#)

51. [Proctor ML, Traubici J, Langer JC, et al. Correlation between radiographic transition zone and level of aganglionosis in Hirschsprung's disease: Implications for surgical approach. J Pediatr Surg 2003; 38:775.](#)
52. [Stranzinger E, DiPietro MA, Teitelbaum DH, Strouse PJ. Imaging of total colonic Hirschsprung disease. Pediatr Radiol 2008; 38:1162.](#)
53. [Doig CM. Hirschsprung's disease and mimicking conditions. Dig Dis 1994; 12:106.](#)
54. [Garcia R, Arcement C, Hormaza L, et al. Use of the recto-sigmoid index to diagnose Hirschsprung's disease. Clin Pediatr \(Phila\) 2007; 46:59.](#)
55. [Lourenção PLTA, Valerini FG, Cataneo AJM, et al. Barium Enema Revisited in the Workup for the Diagnosis of Hirschsprung's Disease. J Pediatr Gastroenterol Nutr 2019; 68:e62.](#)
56. [de Lorijn F, Kremer LC, Reitsma JB, Benninga MA. Diagnostic tests in Hirschsprung disease: a systematic review. J Pediatr Gastroenterol Nutr 2006; 42:496.](#)
57. [Downey EC, Hughes E, Putnam AR, et al. Hirschsprung disease in the premature newborn: a population based study and 40-year single center experience. J Pediatr Surg 2015; 50:123.](#)
58. [Lewis NA, Levitt MA, Zallen GS, et al. Diagnosing Hirschsprung's disease: increasing the odds of a positive rectal biopsy result. J Pediatr Surg 2003; 38:412.](#)
59. [Tang YF, Chen JG, An HJ, et al. High-resolution anorectal manometry in newborns: normative values and diagnostic utility in Hirschsprung disease. Neurogastroenterol Motil 2014; 26:1565.](#)
60. [Meinds RJ, Trzpis M, Broens PMA. Anorectal Manometry May Reduce the Number of Rectal Suction Biopsy Procedures Needed to Diagnose Hirschsprung Disease. J Pediatr Gastroenterol Nutr 2018; 67:322.](#)
61. [Alizai NK, Batcup G, Dixon MF, Stringer MD. Rectal biopsy for Hirschsprung's disease: what is the optimum method? Pediatr Surg Int 1998; 13:121.](#)
62. [Kapur RP. Practical pathology and genetics of Hirschsprung's disease. Semin Pediatr Surg 2009; 18:212.](#)
63. [Croffie JM, Davis MM, Faught PR, et al. At what age is a suction rectal biopsy less likely to provide adequate tissue for identification of ganglion cells? J Pediatr Gastroenterol Nutr 2007; 44:198.](#)

64. [Schofield DE, Devine W, Yunis EJ. Acetylcholinesterase-stained suction rectal biopsies in the diagnosis of Hirschsprung's disease. J Pediatr Gastroenterol Nutr 1990; 11:221.](#)
65. [Lake BD, Puri P, Nixon HH, Claireaux AE. Hirschsprung's disease: an appraisal of histochemically demonstrated acetylcholinesterase activity in suction rectal biopsy specimens as an aid to diagnosis. Arch Pathol Lab Med 1978; 102:244.](#)
66. [Barshack I, Fridman E, Goldberg I, et al. The loss of calretinin expression indicates aganglionosis in Hirschsprung's disease. J Clin Pathol 2004; 57:712.](#)
67. [de Arruda Lourenção PL, Takegawa BK, Ortolan EV, et al. Does calretinin immunohistochemistry reduce inconclusive diagnosis in rectal biopsies for Hirschsprung disease? J Pediatr Gastroenterol Nutr 2014; 58:603.](#)
68. [Janssen Lok M, Rassouli-Kirchmeier R, Köster N, et al. Development of Nerve Fibre Diameter in Young Infants With Hirschsprung Disease. J Pediatr Gastroenterol Nutr 2018; 66:253.](#)
69. [Pratap A, Gupta DK, Tiwari A, et al. Application of a plain abdominal radiograph transition zone \(PARTZ\) in Hirschsprung's disease. BMC Pediatr 2007; 7:5.](#)
70. [Buonpane C, Lautz TB, Hu YY. Should we look for Hirschsprung disease in all children with meconium plug syndrome? J Pediatr Surg 2019; 54:1164.](#)
71. [Mao YZ, Tang ST, Li S. Duhamel operation vs. transanal endorectal pull-through procedure for Hirschsprung disease: A systematic review and meta-analysis. J Pediatr Surg 2018; 53:1710.](#)
72. [Teitelbaum DH, Cilley RE, Sherman NJ, et al. A decade of experience with the primary pull-through for hirschsprung disease in the newborn period: a multicenter analysis of outcomes. Ann Surg 2000; 232:372.](#)
73. [Ramesh JC, Ramanujam TM, Yik YI, Goh DW. Management of Hirschsprung's disease with reference to one-stage pull-through without colostomy. J Pediatr Surg 1999; 34:1691.](#)
74. [Sulkowski JP, Cooper JN, Congeni A, et al. Single-stage versus multi-stage pull-through for Hirschsprung's disease: practice trends and outcomes in infants. J Pediatr Surg 2014; 49:1619.](#)
75. [Bonnard A, de Lagausie P, Leclair MD, et al. Definitive treatment of extended Hirschsprung's disease or total colonic form. Surg Endosc 2001; 15:1301.](#)
76. [Coran AG, Teitelbaum DH. Recent advances in the management of Hirschsprung's](#)

[disease. Am J Surg 2000; 180:382.](#)

77. [Langer JC, Durrant AC, de la Torre L, et al. One-stage transanal Soave pullthrough for Hirschsprung disease: a multicenter experience with 141 children. Ann Surg 2003; 238:569.](#)
78. [Travassos DV, Bax NM, Van der Zee DC. Duhamel procedure: a comparative retrospective study between an open and a laparoscopic technique. Surg Endosc 2007; 21:2163.](#)
79. [Thomson D, Allin B, Long AM, et al. Laparoscopic assistance for primary transanal pull-through in Hirschsprung's disease: a systematic review and meta-analysis. BMJ Open 2015; 5:e006063.](#)
80. [Yanchar NL, Soucy P. Long-term outcome after Hirschsprung's disease: patients' perspectives. J Pediatr Surg 1999; 34:1152.](#)
81. [Bai Y, Chen H, Hao J, et al. Long-term outcome and quality of life after the Swenson procedure for Hirschsprung's disease. J Pediatr Surg 2002; 37:639.](#)
82. [Ludman L, Spitz L, Tsuji H, Pierro A. Hirschsprung's disease: functional and psychological follow up comparing total colonic and rectosigmoid aganglionosis. Arch Dis Child 2002; 86:348.](#)
83. [Dasgupta R, Langer JC. Evaluation and management of persistent problems after surgery for Hirschsprung disease in a child. J Pediatr Gastroenterol Nutr 2008; 46:13.](#)
84. [Chumpitazi BP, Nurko S. Defecation disorders in children after surgery for Hirschsprung disease. J Pediatr Gastroenterol Nutr 2011; 53:75.](#)
85. [Bjørnland K, Pakarinen MP, Stenstrøm P, et al. A Nordic multicenter survey of long-term bowel function after transanal endorectal pull-through in 200 patients with rectosigmoid Hirschsprung disease. J Pediatr Surg 2017; 52:1458.](#)
86. [Thakkar HS, Bassett C, Hsu A, et al. Functional outcomes in Hirschsprung disease: A single institution's 12-year experience. J Pediatr Surg 2017; 52:277.](#)
87. [Neuvonen MI, Kyrklund K, Rintala RJ, Pakarinen MP. Bowel Function and Quality of Life After Transanal Endorectal Pull-through for Hirschsprung Disease: Controlled Outcomes up to Adulthood. Ann Surg 2017; 265:622.](#)
88. [Neuvonen MI, Kyrklund K, Lindahl HG, et al. A population-based, complete follow-up of 146 consecutive patients after transanal mucosectomy for Hirschsprung disease. J Pediatr Surg 2015.](#)

89. [Laughlin DM, Friedmacher F, Puri P. Total colonic aganglionosis: a systematic review and meta-analysis of long-term clinical outcome. *Pediatr Surg Int* 2012; 28:773.](#)
90. [Ralls MW, Coran AG, Teitelbaum DH. Redo pullthrough for Hirschsprung disease. *Pediatr Surg Int* 2017; 33:455.](#)
91. [Davidson JR, Kyrklund K, Eaton S, et al. Sexual function, quality of life, and fertility in women who had surgery for neonatal Hirschsprung's disease. *Br J Surg* 2021; 108:e79.](#)
92. [Langer JC, Rollins MD, Levitt M, et al. Guidelines for the management of postoperative obstructive symptoms in children with Hirschsprung disease. *Pediatr Surg Int* 2017; 33:523.](#)
93. [Langer JC. Persistent obstructive symptoms after surgery for Hirschsprung's disease: development of a diagnostic and therapeutic algorithm. *J Pediatr Surg* 2004; 39:1458.](#)
94. [Han-Geurts IJ, Hendrix VC, de Blaauw I, et al. Outcome after anal intrasphincteric Botox injection in children with surgically treated Hirschsprung disease. *J Pediatr Gastroenterol Nutr* 2014; 59:604.](#)
95. [Roorda D, Oosterlaan J, van Heurn E, Derikx J. Intrasphincteric botulinum toxin injections for post-operative obstructive defecation problems in Hirschsprung disease: A retrospective observational study. *J Pediatr Surg* 2021; 56:1342.](#)
96. [Reding R, de Ville de Goyet J, Gosseye S, et al. Hirschsprung's disease: a 20-year experience. *J Pediatr Surg* 1997; 32:1221.](#)
97. [Hackam DJ, Filler RM, Pearl RH. Enterocolitis after the surgical treatment of Hirschsprung's disease: risk factors and financial impact. *J Pediatr Surg* 1998; 33:830.](#)
98. [El-Sawaf M, Siddiqui S, Mahmoud M, et al. Probiotic prophylaxis after pullthrough for Hirschsprung disease to reduce incidence of enterocolitis: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. *J Pediatr Surg* 2013; 48:111.](#)
99. [Roorda D, Oosterlaan J, van Heurn E, Derikx JPM. Risk factors for enterocolitis in patients with Hirschsprung disease: A retrospective observational study. *J Pediatr Surg* 2021; 56:1791.](#)
100. [Wall N, Kastenber Z, Zobell S, et al. Use of an enterocolitis triage and treatment protocol in children with Hirschsprung disease reduces hospital admissions. *J Pediatr Surg* 2020; 55:2371.](#)
101. [Cheng S, Wang J, Pan W, et al. Pathologically assessed grade of Hirschsprung-associated enterocolitis in resected colon in children with Hirschsprung's disease](#)

- [predicts postoperative bowel function. J Pediatr Surg 2017; 52:1776.](#)
102. [Marty TL, Seo T, Matlak ME, et al. Gastrointestinal function after surgical correction of Hirschsprung's disease: long-term follow-up in 135 patients. J Pediatr Surg 1995; 30:655.](#)
 103. [Pini Prato A, Gentilino V, Giunta C, et al. Hirschsprung disease: do risk factors of poor surgical outcome exist? J Pediatr Surg 2008; 43:612.](#)
 104. [Anupama B, Zheng S, Xiao X. Ten-year experience in the management of total colonic aganglionosis. J Pediatr Surg 2007; 42:1671.](#)
 105. [Pontarelli EM, Ford HR, Gayer CP. Recent developments in Hirschsprung's-associated enterocolitis. Curr Gastroenterol Rep 2013; 15:340.](#)
 106. [Granström AL, Ludvigsson JF, Wester T. Clinical characteristics and validation of diagnosis in individuals with Hirschsprung disease and inflammatory bowel disease. J Pediatr Surg 2021; 56:1799.](#)
 107. [Aworanti OM, McDowell DT, Martin IM, Quinn F. Does Functional Outcome Improve with Time Postsurgery for Hirschsprung Disease? Eur J Pediatr Surg 2016; 26:192.](#)
 108. [Stensrud KJ, Emblem R, Bjørnland K. Anal endosonography and bowel function in patients undergoing different types of endorectal pull-through procedures for Hirschsprung disease. J Pediatr Surg 2015; 50:1341.](#)
 109. [Bischoff A, Frischer J, Knod JL, et al. Damaged anal canal as a cause of fecal incontinence after surgical repair for Hirschsprung disease - a preventable and under-reported complication. J Pediatr Surg 2017; 52:549.](#)
 110. [Moore SW, Albertyn R, Cywes S. Clinical outcome and long-term quality of life after surgical correction of Hirschsprung's disease. J Pediatr Surg 1996; 31:1496.](#)
 111. [Sherman JO, Snyder ME, Weitzman JJ, et al. A 40-year multinational retrospective study of 880 Swenson procedures. J Pediatr Surg 1989; 24:833.](#)
 112. [Ieiri S, Nakatsuji T, Akiyoshi J, et al. Long-term outcomes and the quality of life of Hirschsprung disease in adolescents who have reached 18 years or older--a 47-year single-institute experience. J Pediatr Surg 2010; 45:2398.](#)
 113. [Allin BSR, Opondo C, Bradnock TJ, et al. Outcomes at five to eight years of age for children with Hirschsprung's disease. Arch Dis Child 2020.](#)
 114. [Saadai P, Trappey AF, Goldstein AM, et al. Guidelines for the management of postoperative soiling in children with Hirschsprung disease. Pediatr Surg Int 2019;](#)

[35:829.](#)

115. [Menezes M, Puri P. Long-term outcome of patients with enterocolitis complicating Hirschsprung's disease. Pediatr Surg Int 2006; 22:316.](#)
116. [Hartman EE, Oort FJ, Aronson DC, et al. Explaining change in quality of life of children and adolescents with anorectal malformations or Hirschsprung disease. Pediatrics 2007; 119:e374.](#)
117. [Neuvonen M, Kyrklund K, Taskinen S, et al. Lower urinary tract symptoms and sexual functions after endorectal pull-through for Hirschsprung disease: controlled long-term outcomes. J Pediatr Surg 2017; 52:1296.](#)
118. [Versteegh HP, Johal NS, de Blaauw I, Stanton MP. Urological and sexual outcome in patients with Hirschsprung disease: A systematic review. J Pediatr Urol 2016; 12:352.](#)
119. [Witvliet MJ, van Gasteren S, van den Hondel D, et al. Predicting sexual problems in young adults with an anorectal malformation or Hirschsprung disease. J Pediatr Surg 2018; 53:1555.](#)
120. [Davidson JR, Kyrklund K, Eaton S, et al. Long-term surgical and patient-reported outcomes of Hirschsprung Disease. J Pediatr Surg 2021; 56:1502.](#)

Topic 5903 Version 39.0